Skip to main content

Advertisement

Table 2 Sensitivity of the duration (time to achieve pOTTIS) and relative total cost of annual ivermectin (aCDTI), biannual ivermectin (bCDTI) and annual moxidectin (aCDTM) treatment programmes to the magnitude of the assumed anti-macrofilarial action of ivermectin and moxidectin

From: The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data

Baseline endemicity level (microfilarial prevalence) 1% cumulative reduction in microfilarial production by female adult worms per dose 7% cumulative reduction in microfilarial production by female adult worms per dose 30% cumulative reduction in microfilarial production by female adult worms per dose
Projected duration, in years, of treatment programme (relative cost, in percent) Projected duration, in years, of treatment programme (relative cost, in percent) Projected duration, in years, of treatment programme (relative cost, in percent)
  aCDTI bCDTI (ǂ) aCDTM (ǂ,†) aCDTI bCDTI (ǂ) aCDTM (ǂ,†) aCDTI bCDTI (ǂ) aCDTM (ǂ,†)
Mesoendemic (40%) 21 14 (118%) 12 (65%, 55%) 17 11 (113%) 11 (71%, 63%) 12 9 (126%) 10 (86%, 68%)
Hyperendemic (60%) 33 20 (115%) 18 (67%, 58%) 25 16 (116%) 17 (76%, 66%) 17 14 (138%) 15 (91%, 66%)
Highly-hyperendemic (80%) NA 38 (140%) 30 (76%, 54%) NA 26 (112%) 26 (70%, 63%) 38 22 (114%) 23 (74%, 65%)
  1. ǂPercentage cost relative to aCDTI. Percentage cost relative to bCDTI. NA: Operational thresholds for treatment interruption not attained within the 50-year time horizon (and percentage of costs calculated based on costs of 50 years of aCDTI). The analysis was performed with a 50-year time horizon, therapeutic coverage of 80%, 0.1% systematic non-compliers, perennial transmission, and pOTTIS of <1.4% microfilarial prevalence. Costs do not include value of the (donated) drugs. A summary of the pre-control conditions is provided in Additional file 1: Table S3.